Definium Therapeutics Reports Increased Losses and Advances in Clinical Programs for Q1 2026

Definium Therapeutics, Inc., formerly known as Mind Medicine (MindMed) Inc., reported a significant increase in its financial losses for the first quarter of 2026, with a net loss of $77.1 million compared to a loss of $23.3 million in the same period of the previous year. The company's total operating expenses rose to $59.2 million, up from $32.2 million in the first quarter of 2025, driven primarily by a 78% increase in research and development costs, which reached $41.5 million. This increase was largely attributed to heightened expenses related to the company's lead product candidate, DT120, as well as rising personnel costs.

In terms of financial position, Definium reported cash and cash equivalents of $262.5 million as of March 31, 2026, a slight increase from $257.8 million at the end of 2025. However, the company’s accumulated deficit grew to $659.8 million, reflecting ongoing investments in its clinical programs. The total liabilities also increased to $122.4 million from $107.8 million, primarily due to higher accrued expenses and the change in fair value of the 2022 USD Financing Warrants, which rose to $49.5 million.

Strategically, Definium has made notable advancements in its clinical programs, particularly with DT120, which is being developed for the treatment of generalized anxiety disorder (GAD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). The company has completed enrollment for its Phase 3 clinical trials for GAD and is preparing to initiate trials for MDD and PTSD. The company also announced the completion of its End-of-Phase 2 meeting with the FDA, which supports the advancement of DT120 into pivotal trials.

Operationally, Definium's employee headcount has increased as the company expands its research and development capabilities. The company is actively seeking to enhance its product pipeline through potential collaborations and acquisitions. As of March 31, 2026, Definium had 104 million common shares outstanding, reflecting its ongoing efforts to raise capital through equity offerings. The company anticipates that its current cash reserves will be sufficient to fund operations into 2028, although it acknowledges the need for additional financing to support its ongoing clinical trials and potential commercialization efforts.

Looking ahead, Definium remains focused on advancing its clinical programs and achieving regulatory approvals for its product candidates. The company is also exploring additional funding opportunities to support its growth and development initiatives. However, it cautions that its future operations depend on its ability to secure necessary financing and navigate the complexities of drug development and regulatory processes.